NCT00602550已完成不适用
A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fasting Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 2
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory findings during screening.
排除标准
- •Allergic or adverse responses to zidovudine or any other comparable or similar products.
- •Participation in clinical trial within 30 days of study initiation.
- •Positive blood screen for HIV, Hepatitis B and C.
结局指标
主要结局
Bioequivalence
时间窗: Baseline, Two period, Three day washout
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Zidovudine Under Fed ConditionsHIV InfectionsNCT00601562Roxane Laboratories52
已完成
不适用
Bioequivalency Study of Zolpidem Tartrate Under Fed ConditionsInsomniaNCT00602719Roxane Laboratories30
已完成
不适用
Bioequivalency Study of Zolpidem Tartrate Under Fasting ConditionsInsomniaNCT00601666Roxane Laboratories30
尚未招募
1 期
Bioequivalence of ZidovudinePatients seropositive to Human Immunodeficiency Virus (HIV)Lentiviruses InfectionsRetroviridae InfectionsRNA Viruses InfectionsSexually Transmitted Diseases, ViralImmunologic Deficiency SyndromesImmune System DiseasesVirus DiseasesSexually Transmitted DiseasesHIV InfectionsRPCEC00000263Center for Pharmaceutical Research and Development, Havana, Cuba.30
已完成
1 期
Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed ConditionsTrichomoniasisNCT01591889Roxane Laboratories28